Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know.
about
Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumorsA Perspective of Immunotherapy for Prostate CancershRNA-armed conditionally replicative adenoviruses: a promising approach for cancer therapyIdentifying Individual T Cell Receptors of Optimal Avidity for Tumor AntigensAdoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advancesPotentiality of immunotherapy against hepatocellular carcinomaTrial Watch: Adoptive cell transfer for oncological indicationsAdoptive T-cell therapy for cancer: The era of engineered T cellsTherapy of human papillomavirus-related diseaseTechnical Considerations for the Generation of Adoptively Transferred T Cells in Cancer ImmunotherapyT-Cell-Based Immunotherapy for Osteosarcoma: Challenges and OpportunitiesAre BiTEs the "missing link" in cancer therapy?Prospective study of the evolution of blood lymphoid immune parameters during dacarbazine chemotherapy in metastatic and locally advanced melanoma patientsMeta-analysis of clinical data using human meiotic genes identifies a novel cohort of highly restricted cancer-specific marker genes.Biopolymer implants enhance the efficacy of adoptive T-cell therapy.Colorectal cancer immunotherapy.Immunotherapy for solid tumors--a review for surgeons.Oncolytic measles virus enhances antitumour responses of adoptive CD8+NKG2D+ cells in hepatocellular carcinoma treatment.In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers.Neoadjuvant anti-tumor vaccination prior to surgery enhances survival.Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects.Large-scale expansion of γδ T cells and peptide-specific cytotoxic T cells using zoledronate for adoptive immunotherapy.Identification of prostate-specific G-protein coupled receptor as a tumor antigen recognized by CD8(+) T cells for cancer immunotherapy.Selective inhibition of regulatory T cells by targeting the PI3K-Akt pathway.Conditional ligands for Asian HLA variants facilitate the definition of CD8+ T-cell responses in acute and chronic viral diseases.Neutrophil:lymphocyte ratios and serum cytokine changes after hepatic artery chimeric antigen receptor-modified T-cell infusions for liver metastasesIdentification of special AT-rich sequence binding protein 1 as a novel tumor antigen recognized by CD8+ T cells: implication for cancer immunotherapyNicotinamide inhibits vasculogenic mimicry, an alternative vascularization pathway observed in highly aggressive melanomaMyeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest.EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.Classification of current anticancer immunotherapiesRetargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody.Current advances in T-cell-based cancer immunotherapyReprogramming antitumor immunityNovel role of hematopoietic stem cells in immunologic rejection of malignant gliomas.Adoptive Cell Therapy of Melanoma with Cytokine-induced Killer CellsPersonalized cell transfer immunotherapy for B-cell malignancies and solid cancersId1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation.Requirement of Innate Immunity in Tumor-Bearing Mice Cured by Adoptive Immunotherapy Using Tumor-Draining Lymph Nodes.
P2860
Q26741260-BB907D32-D69A-4A7E-8161-270925DF1FF9Q26741277-A5E03201-9735-4974-A336-A1D172C77F52Q26765364-87D7090C-2F0F-4B1F-9DB4-2AE873D9D261Q26774669-68BEC246-27AF-435D-AD85-7A9BD6C5F830Q26775720-B7506111-CEC3-452A-B02F-1F94289BE08DQ26784228-3BA87148-5E0B-4A51-AEC8-FB86FB0DEF6FQ26785545-F2015A33-382B-4EFB-9279-9E8ECC292BE8Q26800611-F38C541F-D33D-43AA-A4DD-FBBC72762B95Q27007473-795D9419-B97B-47DB-A2E1-712EAF7BDA41Q28073563-F3856762-2266-4CE1-8017-4443CB437BD3Q28074619-45206490-5FE2-4AEA-8661-7EA4E253FE92Q28083907-24F46B66-3C40-4688-9324-29A204BEEFC2Q28542660-7D61B2F4-E922-4E8B-81A0-848722649AB6Q30558949-04E3CD73-FEF6-474B-B712-6AE410C05D93Q30614247-289AF236-549F-435A-A008-832C215CEA06Q33701465-F2A7E9FC-1F88-489F-B3E3-5E1526AF7CCFQ33709232-8C47CC00-0362-4E80-84D1-A23F0B4A4672Q33899522-827E0A65-87CC-40F1-8434-5831C68EEB69Q34048101-08D3C4E9-2AC8-4806-8B02-9001753A04C8Q34145877-1F8115E6-9B7B-459F-AFAB-28E83383353AQ34256494-1D05570C-CCD4-47C8-935C-62162D96D245Q34372167-F8E5B366-C736-4D33-B8A4-D65B94934CECQ34429991-BA12D7B8-4C49-4AA8-9E01-2F46B158D82DQ34458364-13D66D0A-06F5-4AD8-93F3-3B7E926EA89FQ34529083-AE4C7A80-664B-431B-95C5-0911B6292B71Q34577127-71755A70-F31E-4C7E-A985-0850820AAC3AQ34599387-60B6236A-8186-40B0-A6D7-A39AA430A825Q34603154-CF13A28D-6BF1-48A0-9E22-7435733D3EFCQ34634616-1F4762D3-5AC8-4F16-AE5D-A16F0A72CC8BQ34892977-E84E367E-8829-4B54-A924-189345E52E01Q35145144-7E60C417-3F6E-4CE4-A607-F8230CF72287Q35149637-1C20935E-8062-4468-913F-C78A7FC7ED46Q35152029-B1336AED-2C36-4E54-AAA5-C8D7D86EF24CQ35215158-15574A37-41DD-4A52-ABED-EE7E6130DD20Q35216812-9F336C77-D79C-41BA-B04C-0DEC6F9CF27DQ35507524-B9EA7A36-605D-4C70-9251-16EB447A1673Q35543911-CE9993AA-0448-4E57-AE4D-7872C2FC479BQ35568556-172EE671-73F3-47B0-B196-5E4092DA1193Q35579455-6ED2EF28-85D0-42C0-B91C-378E8FA550D3Q35605398-61C00F4B-191B-4349-85BF-E2FD50D10748
P2860
Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know.
@en
Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know.
@nl
type
label
Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know.
@en
Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know.
@nl
prefLabel
Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know.
@en
Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know.
@nl
P2860
P1476
Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know
@en
P2093
Steven A Rosenberg
P2860
P304
P356
10.1038/NRCLINONC.2011.116
P407
P577
2011-08-02T00:00:00Z